Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: An in vivo study

被引：23
作者：
Artang R. [1 ,2 ]
Frandsen N.J. [3 ]
Nielsen J.D. [1 ]
机构：
[1] Coagulation Laboratory, Gentofte University Hospital, Hellerup
[2] Mercy Heart Center, Sioux City, Iowa
[3] Department of Cardiology, Gentofte University Hospital, Hellerup
来源：
Thrombosis Journal | / 7卷 / 1期
关键词：
Therapeutic Range; Unfractionated Heparin; Healthy Male Volunteer; Dalteparin; Antithrombotic Effect;
D O I：
10.1186/1477-9560-7-14
中图分类号：
学科分类号：
摘要：
Background: Low molecular weight heparin (LMWH) is in vast usage for treatment of thromboembolic diseases such as deep venous thrombosis and acute coronary syndromes. There are certain clinical situations where a quick point of care testing of the effect of LMWH would be useful. At this point there are no point of care devices available in the market for monitoring the effect of LMWH. Thrombelastography (TEG) evaluates the viscoelastic properties of blood during coagulation. The clinical application of TEG in monitoring LMWH treatment is not yet well defined. The purpose of this in vivo study was to systematically evaluate the most suitable TEG parameters for evaluation of the antithrombotic effect of LMWH. We furthermore evaluated for the first time the usefulness of the composite TEG parameter the Thrombodynamic Ratio (TDR) in monitoring LMWH treatment. Methods: Healthy male volunteers (n = 7) were injected subcutaneously with the LMWH dalteparin 120 IU/kg. TEG parameters and antifactor Xa levels were measures at baseline, 2, 4, 5 and 24 hours after the injection. Correlation between TEG parameters and antiXa were calculated. The sensitivity and specificity of the TEG parameters for plasma levels of antiXa in the therapeutic range of 0.5 - 1.0 U/ml were calculated. Results: All basic TEG parameters correlated significantly with antiXa levels. Among the basic parameters, the TEG reaction time R had the best correlation with antiXa levels with the most favorable combination of sensitivity and specificity for the therapeutic range of antiXa levels (r = 0.82, p < 0.0001, sensitivity 68%, specificity 100%). The composite TEG parameter TDR demonstrated the best correlation with antiXa levels, and an even more favorable combination of sensitivity and specificity compared to any of the basic parameters (r = - 0.87, p < 0.0001, sensitivity 95%, specificity 79%). Conclusion: The TEG reaction time R and TDR are the most suitable TEG parameters for evaluation of the antithrombotic effect of dalteparin with a highly significant correlation with antiXa levels in healthy male volunteers. Measures for uniform clinical use of these parameters are proposed. Larger clinical trials are needed to correlate R and TDR with clinical outcomes. © 2009 Artang et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 21 条
[1]  
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group, Lancet, 347, pp. 561-568, (1996)
[2]  
Klein W., Buchwald A., Hillis S.E., Monrad S., Sanz G., Turpie A.G., Meer J., Olaisson E., Undeland S., Ludwig K., Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC), Circulation, 96, pp. 61-68, (1997)
[3]  
Long-term low-molecular-mass heparin in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. FRISC II Investigators, Lancet, 354, pp. 701-707, (1999)
[4]  
Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S., Langer A., Califf R.M., Fox K.A., Premmereur J., Bigonzi F., A comparison of low-molecular-eight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group, N Engl J Med, 337, pp. 447-452, (1997)
[5]  
Antman E.M., McCabe C.H., Gurfinkel E.P., Turpie A.G., Bernink P.J., Salein D., Bayes De Luna A., Fox K., Lablanche J.M., Radley D., Premmereur J., Braunwald E., Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial, Circulation, 100, pp. 1593-1601, (1999)
[6]  
Moliterno D.J., Mukherjee D., Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine, Am Heart J, 140, 6 SUPPL, (2000)
[7]  
Backe S.K., Lyons G.R., High-dose tinzaparin in pregnancy and the need for urgent delivery, Br J Anaesth, 89, pp. 331-334, (2002)
[8]  
Hartert H., Schaeder J.A., The physical and biological constants of thrombelastography, Biorheolgy, 1, pp. 31-39, (1962)
[9]  
Chandler W.L., The thromboelastography and the thromboelastograph technique, Semin Thromb Hemost, 21, SUPPL 4, pp. 1-6, (1995)
[10]  
Zuckerman L., Cohen E., Vagher J.P., Woodward E., Caprini J.A., Comparison of thrombelastography with common coagulation tests, Thromb Haemost, 46, pp. 752-756, (1981)
123